Results 11 to 20 of about 15,828 (290)

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. [PDF]

New England Journal of Medicine, 1999
BACKGROUND: In patients with refractory unstable angina, the platelet glycoprotein IIb/IIIa-receptor antibody abciximab reduces the incidence of cardiac events before and during coronary angioplasty.
Adgey, J. (Jennifer), Berger, J. (Jürgen), Goldmann, B. (Britta), Hamm, C.W. (Christian), Heeschen, C. (Christopher), Kootstra, J.G. (Jille), Miguel, C.M. (Carlos), Rutsch, W.R. (Wolfgang), Simoons, M.L. (Maarten), Vahanian, A.S. (Alec)   +9 more
core   +3 more sources

Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives

Therapeutics and Clinical Risk Management, 2014
Artur Dziewierz,1 Tomasz Rakowski,1 Dariusz Dudek2 12nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland; 2Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland Abstract ...
Dziewierz A, Rakowski T, Dudek D
doaj   +2 more sources

Abciximab in the treatment of coronary artery disease [PDF]

Reviews in Health Care, 2013
Antiplatelet therapy constitutes a cornerstone in the strategies aimed at the effective management of acute coronary syndrome. Abciximab is the oldest and most commonly used intravenous antiplatelet agent in this context, in particular when an invasive strategy is adopted. It is very commonly used in more unstable and high- risk patients.
Jayasinghe, Rohan, Maxwell, Ryan, Murdoch, Dale   +2 more
openaire   +6 more sources

Modeling Versus Balancing Approaches to Addressing Instrumental Variables in Weighting: A Comparison of the Outcome-Adaptive Lasso, Stable Balancing Weighting, and Stable Confounder Selection. [PDF]

Pharmacoepidemiol Drug Saf
ABSTRACT Background Variable selection is essential for propensity score (PS)‐weighted estimators. Recent work shows that including instrumental variables (IVs), associated with only treatment but not with the outcome, can impact both the bias and precision of the PS‐weighted estimators.
Choi BY, Brookhart MA.
europepmc   +2 more sources

Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction [PDF]

New England Journal of Medicine, 2002
BACKGROUND As compared with thrombolytic therapy, primary percutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarction reduces the rates of death, reinfarction, and stroke, but recurrent ischemia, restenosis, and reocclusion of ...
Gregg W. Stone, Cindy L. Grines, David A. Cox, Eulogio Garcı́a, James E. Tcheng, John J. Griffin, Giulio Guagliumi, Thomas Stuckey, Mark Turco, John D. Carroll, Barry D. Rutherford, Alexandra J. Lansky   +11 more
openalex   +2 more sources

Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion [PDF]

, 2002
BACKGROUND: GPIIb/IIIa inhibitors abciximab and eptifibatide have been shown to inhibit platelet aggregation in ischemic heart disease. Our aim was to test the efficacy of abiciximab (Reo Pro) or eptifibatide (Integrilin) alone or in combination with ...
Silva Bertuglia, Andrea Giusti
openalex   +4 more sources

Sustainable Practices in Anti-VEGF Therapy: A 15-Year Bibliometric Analysis of Ranibizumab for Age-Related Macular Degeneration. [PDF]

J Ophthalmol
Objective: A bibliometric analysis was performed in the domain of ranibizumab and age‐related macular degeneration (AMD) to delineate current trends in international research dynamics and to provide a visual representation of research hotspots and challenges associated with ophthalmic drugs over the past 15 years.
Xiaodong L, Xia C, Xuewei Q, Dandan W, Yi Y, Zhilin L.   +5 more
europepmc   +2 more sources

Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article. [PDF]

Cardiovasc Ther
Acute coronary syndrome (ACS) is one of the most common leading global causes of mortality, encompassing ST‐segment elevation myocardial infarction (STEMI), non‐ST‐segment elevation myocardial infarction (NSTEMI), and unstable angina (UA). Percutaneous coronary intervention (PCI) has become a pivotal therapeutic approach for ACS, underscoring the ...
Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, Sun S, Zhang J, Liu X.   +8 more
europepmc   +2 more sources

Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization [PDF]

New England Journal of Medicine, 2001
BACKGROUND In the setting of percutaneous coronary revascularization, agents in the class known as platelet glycoprotein IIb/IIIa inhibitors have significantly reduced the incidence of death or nonfatal myocardial infarction at 30 days.
Eric J. Topol, David J. Moliterno, Howard C. Herrmann, Eric R. Powers, Cindy L. Grines, David J. Cohen, Eric A. Cohen, Michel E. Bertrand, Franz‐Josef Neumann, Gregg W. Stone, Peter M. DiBattiste, Steven J. Yakubov, Paul DeLucca, Laura A. Demopoulos   +13 more
openalex   +2 more sources

Glycoprotein IIb/IIIa Inhibitors Use and Outcome after Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction [PDF]

, 2014
Aims. We investigate the effect of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors on long-term outcomes following percutaneous coronary intervention (PCI) after non-ST elevation myocardial infarction (NSTEMI). Meta-analyses indicate that these agents are
Antoniou, S, Gallagher, S, Howard, JP, Jones, DA, Knight, C, Mathur, A, Rathod, K, Weerackody, R, Wragg, A, Wright, P   +9 more
core   +8 more sources